Sorrento Therapeutics' GAAP loss for 3 months of 2022 was $40.54 million, compared to a profit of $2.418 million in the previous year. Revenue increased by 29% to $18.385 million compared to $14.255 million a year earlier.
Sorrento Therapeutics' GAAP loss for 3 months of 2022 was $40.54 million, compared to a profit of $2.418 million in the previous year. Revenue increased by 29% to $18.385 million compared to $14.255 million a year earlier. 
investors.sorrentotherapeutics.com
English (US) 